A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma

被引：0
|
作者：
Budde, L. Elizabeth
Martin, Daniel B.
Philip, Mary
Shustov, Andrei R.
Gooley, Theodore
Chen, Tara L.
Libby, Edward N.
Chen, Eric Y.
Kojouri, Kiarash
Langerak, Alan
Roden, Jennifer E.
Kammerer, Britt E.
Knudsen, Nancy L.
Smith, Stephen Douglas
Press, Oliver W.
Gopal, Ajay K.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[6] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[7] Grp Hlth Permanente, Bellevue, WA USA
[8] Skagit Valley Hosp, Reg Canc Care Ctr, Mt Vernon, WA USA
[9] St Alphonsus Reg Med Ctr, Boise, ID USA
[10] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8533
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    R Sakai
    K Ohmachi
    F Sano
    R Watanabe
    H Takahashi
    H Takasaki
    M Tanaka
    Y Hattori
    H Kimura
    M Takimoto
    T Tachibana
    E Tanaka
    Y Ishii
    Y Ishiyama
    M Hagihara
    K Miyazaki
    K Yamamoto
    N Tomita
    K Ando
    Annals of Hematology, 2019, 98 : 2131 - 2138
  • [42] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    Sakai, R.
    Ohmachi, K.
    Sano, F.
    Watanabe, R.
    Takahashi, H.
    Takasaki, H.
    Tanaka, M.
    Hattori, Y.
    Kimura, H.
    Takimoto, M.
    Tachibana, T.
    Tanaka, E.
    Ishii, Y.
    Ishiyama, Y.
    Hagihara, M.
    Miyazaki, K.
    Yamamoto, K.
    Tomita, N.
    Ando, K.
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2131 - 2138
  • [43] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
  • [44] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
  • [45] Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)
    Xu, Pengpeng
    Li, Wang
    Cheng, Shu
    Zhao, Wei Li
    BLOOD, 2023, 142
  • [46] A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma
    Qingyuan Zhang
    Rong Tao
    Zhenyu Li
    Haiyi Guo
    Meng Ji
    Lu Zhang
    Jane Huang
    Fu Lina
    Jinhua Zhong
    Jianfeng Zhou
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2503 - 2506
  • [47] Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
    Tobinai, K
    Igarashi, T
    Itoh, K
    Kobayashi, Y
    Taniwaki, M
    Ogura, A
    Kinoshita, T
    Hotta, T
    Aikawa, K
    Tsushita, K
    Hiraoka, A
    Matsuno, Y
    Nakamura, S
    Morio, S
    Ohashi, Y
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 821 - 830
  • [48] A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma
    Moss, Jessica J.
    Howard, Dianna
    Van Meter, Emily
    Hayslip, John
    BLOOD, 2011, 118 (21) : 706 - 706
  • [49] A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
    Maddocks, Kami
    Christian, Beth
    Jaglowski, Samantha
    Flynn, Joseph
    Jones, Jeffery A.
    Porcu, Pierluigi
    Wei, Lai
    Jenkins, Cynthia
    Lozanski, Gerard
    Byrd, John C.
    Blum, Kristie A.
    BLOOD, 2015, 125 (02) : 242 - 248
  • [50] RITUXIMAB, BENDAMUSTINE AND CYTARABINE (R-BAC) IN PATIENTS WITH RELAPSED-REFRACTORY AGGRESSIVE B- AND T-CELL LYMPHOMA
    Tisi, M. C.
    Paolini, R.
    Piazza, F.
    Ravelli, E.
    Carli, G.
    Perbellini, O.
    Ruggeri, M.
    Visco, C.
    HAEMATOLOGICA, 2017, 102 : 51 - 51
12345